Application No.: Not Yet Assigned Docket No.: 01017/39525

## AMENDMENTS TO THE CLAIMS

The amendments to the claims will replace all prior versions, and listings of the claims in the application.

## Listing of the Claims:

Claims 1-71 (canceled)

- 72. (new) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
  - (a) the nucleotide sequence as set forth in SEQ ID NO: 1;
- (b) a nucleotide sequence encoding the polypeptide as set forth in SEQ ID NO: 2; and
  - (c) a nucleotide sequence fully complementary to (a) or (b).
- 73. (new) An isolated polynucleotide comprising a nucleic acid sequence that is at least 90% identical to the sequence of the nucleic acid molecule of claim 72, wherein the polynucleotide encodes a polypeptide that is an IL-17 receptor like protein.
- 74. (new) An isolated nucleic acid molecule that encodes a polypeptide that is an IL-17 receptor like protein, wherein the nucleic acid molecule hybridizes to the complement of the nucleic acid molecule of claim 72 under the following stringent conditions: a final wash of 0.015 M sodium chloride and 0.0015 M sodium citrate at 65-68°C.
- 75. (new) A vector comprising the nucleic acid molecule of any one of claims 72, 73 or 74.
  - 76. (new) A host cell comprising the vector of claim 75.
  - 77. (new) The host cell of claim 76 that is a eukaryotic cell.
  - 78. (new) The host cell of claim 77 that is a prokaryotic cell.

Application No.: Not Yet Assigned Docket No.: 01017/39525

79. (new) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 76 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

- 80. (new) The process of claim 79, wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native IL-17 receptor like polypeptide operatively linked to the DNA encoding the IL-17 receptor like polypeptide.
- 81. (new) A composition comprising a nucleic acid molecule of any one of claims 72, 73, or 74 and a pharmaceutically acceptable formulation agent.
- 82. (new) A composition of claim 81 wherein said nucleic acid molecule is contained in a viral vector.
- 83. (new) A viral vector comprising a nucleic acid molecule of any one of claims 72, 73, or 74.